WO2000053287A1 - Ensemble filtrant de leucocytes, milieu et procede - Google Patents

Ensemble filtrant de leucocytes, milieu et procede Download PDF

Info

Publication number
WO2000053287A1
WO2000053287A1 PCT/US2000/006003 US0006003W WO0053287A1 WO 2000053287 A1 WO2000053287 A1 WO 2000053287A1 US 0006003 W US0006003 W US 0006003W WO 0053287 A1 WO0053287 A1 WO 0053287A1
Authority
WO
WIPO (PCT)
Prior art keywords
filter
fluid
set forth
media
leukocytes
Prior art date
Application number
PCT/US2000/006003
Other languages
English (en)
Inventor
Robertson D. Davenport
Thomas F. Haddock
Galina N. Fomovskaia
Oksana P. Penezina
Original Assignee
Whatman, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whatman, Inc. filed Critical Whatman, Inc.
Priority to AU35168/00A priority Critical patent/AU3516800A/en
Publication of WO2000053287A1 publication Critical patent/WO2000053287A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D39/00—Filtering material for liquid or gaseous fluids
    • B01D39/14—Other self-supporting filtering material ; Other filtering material
    • B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
    • B01D39/18—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being cellulose or derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D39/00—Filtering material for liquid or gaseous fluids
    • B01D39/14—Other self-supporting filtering material ; Other filtering material
    • B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
    • B01D39/1607—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous
    • B01D39/1623—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous of synthetic origin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D39/00—Filtering material for liquid or gaseous fluids
    • B01D39/14—Other self-supporting filtering material ; Other filtering material
    • B01D39/20—Other self-supporting filtering material ; Other filtering material of inorganic material, e.g. asbestos paper, metallic filtering material of non-woven wires
    • B01D39/2003—Glass or glassy material
    • B01D39/2017—Glass or glassy material the material being filamentary or fibrous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
    • A61M1/3633—Blood component filters, e.g. leukocyte filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0439—White blood cells; Leucocytes

Definitions

  • the invention relates to an apparatus, media, and method for filtering blood, particularly an apparatus and method for removing leukocytes from blood.
  • This condition has many ramifications.
  • the patient may become refractory to platelet transfusions whereby transfused platelets are destroyed by the recipient's immune system. This is a serious condition in patients requiring multiple transfusions, such as oncology patients.
  • HLA sensitization may also give rise to non- hemolytic febrile transfusion reactions upon subsequent transfusions, making matching for organ transplants extremely difficult and cause failure of bone marrow transplants .
  • CMV cytomegalovirus
  • PRBCs and PCs usually contain 10 8 to 10 9 leukocytes per unit. Most transfusion recipients receive two or more units of PRBCs and pools of six to ten PCs at a time. Thus a patient may receive more than 10 10 donor leukocytes with each transfusion.
  • many patients today with diseases such as leukemia or liver disease receive numerous blood transfusions.
  • Recent investigations have suggested that the total number of leukocytes transfused is the critical factor in preventing leukocyte-related complications. Febrile transfusion reactions may be prevented by reducing the transfused leukocyte load to a level of less than 5 X 10 8 WBC, whereas preventing of HLA alloimmunization may require levels of less than 5 X 10 6 WBC (Klein et al . , 1992) .
  • Currently available filters may not consistently achieve sufficient reduction to prevent HLA immunization. The prevention of GVHD requires even greater levels of leukocyte reduction, which exceeds the capacity of current filters .
  • Leukocyte depletion of blood components can take place either at the bedside or in the blood center where the blood components are manufactured. While both procedures now take place, it is generally felt that leukocyte depletion at the time of manufacture is preferable, since it prevents the release of activation or breakdown products into the blood.
  • leukodepleted PRBC and PC are made from a single donation, each must be individually filtered. This necessitates one filter for the PRBC. After enough platelets have been pooled to constitute a therapeutic dose (usually collected from 6 to 10 whole-blood units) , a separate filter for the platelets is required.
  • a filter and method for removing leukocytes from blood components by employing their specific biochemical binding sites would be desirable. This would permit stronger and more specific leukocyte binding forces, and hence allow the filtration of whole blood.
  • LRV Log Reduction Value
  • the leukocyte-reduction filter and method of the present invention permit greater levels of leukocyte reduction than are currently achievable.
  • LRVs of 4 or greater may be reliably produced.
  • This provides a consistent leukocyte reduction at clinically sufficient levels and, due to the filter's specificity, it can filter whole blood as well as blood components (PRBCs or PCs) . Not only would this decrease costs by using one instead of two filters, but it will improve the quality of platelet concentrates by eliminating undesirable leukocyte activation and breakdown products.
  • a product with higher levels of removal, as well as the possible filtration of whole blood, is a marked advance in transfusion technology.
  • a filter assembly for removing leukocytes from a fluid.
  • the filter assembly includes a housing having inlet means disposed in fluid communication with the chamber for allowing a flow of fluid into the chamber, outlet means disposed in fluid communication with the chamber for allowing a flow of fluid from the chamber and biologically-active filter means disposed within the chamber for removing leukocytes from the fluid passing through the assembly.
  • a filter media for removing leukocytes from a fluid which includes a biological moiety for removing leukocytes from the fluid.
  • a method of removing leukocytes from a fluid by passing a fluid which contains leukocytes through a biologically-active filter for selectively and biochemically binding and retaining leukocytes to the filter from the fluid.
  • Figure 1 is a cross-sectional drawing of a typical filter design embodying the present invention
  • Figure 2 is a graph illustrating the number of leukocytes per microliter separated from whole blood using magnetic beads coated with anti- CD62L versus beads coated with Mouse IgG as an indicator of the viability of the CD62L (L- selectin) over a twenty-four hour experimental interval;
  • Figure 3 illustrates the viability of CD62L expressed on neutrophils and lymphocytes
  • Figure 4 illustrates CD62L viability for the monocytes and eosinophils
  • Figure 5 is a graph illustrating RBC counts in the supernatant after incubation of washed RBC from whole blood concentration with control and galactose imprinted polymers both with and without inhibition by galactose;
  • Figure 6 is a graph illustrating RBC counts in the supernatant after incubation of washed RBC from CPDA-1 whole blood with control and galactose imprinted polymers
  • Figure 7 is a graph illustrating the determination of the Hb concentrations of the control and galactose imprinted samples in the supernatant using the spectophotometric method.
  • Figure 8 is a graph illustrating the platelet and leukocyte retention on the acrylamide treated GF/L media.
  • a filter assembly is generally shown and designated by the reference numeral 10.
  • the filter assembly 10 is of a conventional filter design as is well known in the art.
  • the filter assembly 10 includes a housing 12 which defines an inner chamber 14.
  • An inlet 16 disposed in fluid communication with the chamber 14 allows for a flow of fluid to enter into the chamber 14.
  • the filter assembly 10 further includes an outlet 18 disposed in fluid communication with the chamber 14 which allows the flow of fluid to exit from the chamber 14.
  • the assembly 10 further includes a biologically-active filter 20 disposed within the chamber 14 for removing leukocytes from the fluid passing through the assembly 10.
  • the housing 12 can be manufactured from suitable medical plastic materials, for example polypropylenes, polyolefins, polyesters, polyamides, polycarbonates, polystyrenes, styrenes, co- polymers, and fluoroplastics .
  • suitable medical plastic materials for example polypropylenes, polyolefins, polyesters, polyamides, polycarbonates, polystyrenes, styrenes, co- polymers, and fluoroplastics . This list is not meant to be exhaustive and can include other suitable materials without departing from the present invention.
  • the housing 12 is preferably made from two housing halves 22, 24, the two housing halves 22, 24 defining two walls 22, 24 of the housing 12.
  • the housing halves 22, 24 can be connected together by means well known in the art such as by gluing, sonic welding, or any other fusion-type bonding, but is not limited to these methods .
  • the inlet generally indicated at 16 is located proximate to a first end 13 of the housing 12, the inlet 16 being in fluid communication with the chamber 14 for allowing the flow of fluid into the chamber 14.
  • the outlet, generally shown at 18, is proximate to a second end 15 of the housing 12 and in fluid communication with the chamber 14 for allowing a flow of fluid from the chamber 14 out of the housing 12.
  • a biologically-active filter 20 can be supported by the housing 12 and includes a surface layer of covalently-bonded or otherwise strongly retained (e.g., by dendrimers) ligands such as carbohydrates, lipids, proteins, and other moieties known to those skilled in the art, to which leukocytes in donor blood will bind specifically and efficiently, through biologic receptors.
  • ligands can be attached by polymeric chains extending from their attachment points on the surface of the polymers.
  • carbohydrates can be disposed at a distance from the surface of the polymers.
  • These polymers can be comprised of materials to which blood cells (including platelets) have low affinity. The density of the chains on the surface can serve to shield the underlying substrate from blood cells that may adhere to the substrate.
  • the biologically-active filter 20 can be a mat, web, or solid material with the ligands, such as carbohydrates, with the ligands affixed thereto or can include an internal surface of the chamber 14 coated with the ligands.
  • Two main criteria for ligand selection are that the ligand:
  • Bioly-active is defined to include the interaction of biological molecules having specific affinity and specificity for each other, e.g., enzyme-substrate. That is, the ligands bind with specificity to other biological moieties or molecules in a manner such as that exhibited by enzyme-substrate binding. This would include specific means such as covalent binding, hydrogen binding and the like.
  • the ligands of the present invention can include mannose phosphate and fucoidan polysaccharides, two established carbohydrate ligands of L-selectin. This selection of candidate ligands can be based on established ligands for L-selectin (see below) . These oligosaccharides and polysaccharides are available commercially, or can be synthesized from readily available precursors .
  • carbohydrate ligands can be polysaccharides and oligosaccharides including Lewis-x, Lewis-a, sialyl-Lewis x, sialyl-Lewis a, mannose-6- phosphate, polyphosphosmannose ester (PPME) , fucoidan, and the glycolipid 3-O-sulfate- galactosyl ceramide . Additionally, synthesized sulfate derivatives of Lewis-a and Lewis-x can be used. In addition, the ligands could be another naturally-occurring or synthesized molecule.
  • imprinted polymers are attached to the fibrous substrate of the filter.
  • Imprinted polymers are made from a growth of polymers around an active or target molecule which simulate their form and charge distribution and the active or target molecules are subsequently removed from the initial active molecule.
  • the resultant "imprinted polymer” behaves as a complement receptor to the initial molecule.
  • These imprinted polymers can be made from materials that will not activate platelets. Further, they can be grown directly on the substrate fibers .
  • Acceptable substrate media or solid support material and their surface treating chemicals for the filter means 20 of the present invention can include nylon, for its easy bonding characteristics, and polyester, as it is commonly used in blood-filtration as its surface can be easily derivatized. These two substrates can be treated, for example, with NaOH under a range of conditions to produce carboxylic acid and hydroxyl groups on the polyester, and carboxylic acid and amines on nylon. Cellulose, since it has many hydroxyls on the surface, and is easy to derivatize can also be a suitable material for the substrate of the biologically-active filter 20. Basic treatment of polyester and nylon substrates will produce surface structures on which carbohydrate ligands or polymeric attachment chains can be attached.
  • Platelet adhesion can be reduced by coating any of these substrates with, for example, acrylamide attachment sites (as discussed below) and these acrylamide sites would also be easily derivatized to attach the carbohydrate ligands.
  • Nylon, polyester and cellulose acetate would still be likely candidates for substrate material, since they are readily processed to produce nonwoven fibrous mats which could be coated to produce the final filtration media, as noted below.
  • Nylon and polyester are both excellent filtration media with strong fibers but, more importantly, their surfaces can be hydrolyzed to provide free amines and hydroxyls respectively as well as free carboxylic acids. This hydrolysis breaks the bonds in the polymer chain and thereby weakens it structurally, but only on the fiber's surface .
  • Regenerated cellulose has hydroxyls readily available but is a weaker material.
  • Cellulose acetate fibers are also weaker but can be readily hydrolyzed to produce free hydroxyls without significant chain scission.
  • Plastic fibers or sheets can be hydrolyzed in NaOH (various temperatures and times) as needed.
  • appropriate hydrolysis conditions to obtain ample free amines (from nylon) as detected by Ninhydrin Reagent spray are obtained.
  • Polyester hydrolysis requires harsher conditions and surface hydrolysis to free carboxylic acids is detected by the color change induced in a pH indicator dye. If required, acrylamides are attached to the free amines and hydroxyls on nylon, or on the free hydroxyls and carboxylic acid on polyester.
  • Nylon 6,6, poly (hexamethylene adipamide) is available from AIN Plastics, Inc., Southfield, Michigan as 1/16-inch sheets.
  • Cerex TM filter media is available from RFiberweb Group at various basis weights appropriate for efficient blood filtration.
  • Polyester, polyethylene terephthalate, sheets can be obtained from AIN Plastics as type A, cloudy (i.e., crystalline) sheets of 0.010 inch thickness.
  • Polyester filtration media can be obtained from Freudenberg, from Hollinsworth & Vose, or from Fiberweb Group, in various basis weights.
  • Membranes i.e., surface filters
  • the filters 20 are preferably filters with depth which are more open and which will not be so easily clogged.
  • depth filters allow extended exposure
  • Depth filters also called filtration media, are porous mats of fibers. They have a nominal pore size rating but this is a very crude approximation.
  • Basis weight measured in ounces per square yard, is determined by the thickness of individual fibers, distance between fibers, and thickness of the mat; all these affect filtration efficiency and will be varied within a suitable range.
  • Effective pore sizes can range from, for example, seven microns to 15-20 microns as red blood cells must pass through the filter. This range is provided for example purposes only and is not intended to be all inclusive as other suitable pore size ranges can be contemplated.
  • the substrate or solid support media must also be mechanically strong and available as porous webs suitable for blood filtration.
  • Pure cellulose filter paper has an abundance of hydroxyl groups but is not very strong when wet.
  • Nylon and polyester are both excellent filtration media with strong fibers but they have practically no reactive groups as supplied.
  • the surfaces of nylon and polyester fibers can be hydrolyzed to provide free amines and hydroxyls respectively as well as free carboxylic acids. This hydrolysis breaks the bonds in the polymer chain and thereby weakens it structurally, but only on the fiber's surface.
  • Platelet adhesion to the substrate can be reduced by using, for example, acrylamide or acrylic acid attachment sites on the surface of the substrate material .
  • Other inhibitors of platelet adhesion can include polymers that minimize platelet adhesion including poly (ethylene) /poly (propylene oxide) /poly (ethylene oxide) triblock copolymers (Pluronics)
  • the attachment procedure is very versatile and only minimally dependent on the type of substrate, allowing attachment of various types of block polymer chains.
  • concentration of monomers on the substrate surface to control the graft density can be altered, and hence the density of polymeric chains extending from the surface.
  • Acrylic acids are used as the attachment points, since acrylamides are water soluble and are easily worked. Acrylic acid chains can be grown to different lengths from the substrate surface. This allows variation of the effective surface density of carbohydrates, as well as to control the spectrum of cell sizes that may "push aside" the carbohydrate chains and contact the substrate surface. The latter effect is used to shield the uncoated substrate surface from platelets. There is likely an upper limit to this density above which cells of the sizes of platelets cannot reach the original surface. In this case, the adhesion of platelets is effectively blocked by the presence of the polymeric chains attached to the surface. In- addition, inserting various block polymer sections in the carbohydrate-ligand- containing polymers attached to the surface can be used.
  • L-selectin appears to be the foremost candidate for exploitation by a leukocyte filtration device.
  • the distribution of L-selectin (also called CD62L, Leu-8, MEL-14) on blood leukocytes includes lymphocytes, neutrophils, monocytes and eosinophils where it is constituatively expressed. L-selectin mediated binding will occur under conditions of shear flow. Leukocyte rolling along the blood vessel wall, prior to firm attachment and extravasation involves L-selectin.
  • the natural ligands of L- selectin appear to be sialyl-Lewis x (sLe x ) and sialyl-Lewis a (sLe a ) antigens. Data show that
  • L-selectin is expressed on most blood leukocytes for up to twenty-four hours when stored in CPDA-1
  • leukocyte adhesion molecules with carbohydrate ligands include E-selectin and P-selectin which are not found on resting leukocytes, but are expressed by activated leukocytes. Both E-selectin and P-selectin have been shown to bind sLe x , although with different affinities than L-selectin. sLe x and other fucosylated lactosamines are also found on circulating neutrophils, monocytes, and some lymphocytes .
  • Lewis antigens In addition to Lewis antigens, a number of carbohydrate structures may bind to L-selectin including mannose-6-phosphate, a yeast core polysaccharide PPME, sulfated polysaccharides such as fucoidan, and the glycolipid 3-O-sulfate- galactosyl ceramide . Modification of Lewis antigens may increase the affinity of E-selectin binding (Nelson et al . , 1993). Addition of 8- methocycarbonyloctyl aglycone to N-acetyl glucosamine of sLe x or sLe a increases binding twofold.
  • CD34+ stem cells express an L-selectin ligand
  • lectins can be used to bind leukocytes.
  • a lectin is a carbohydrate binding protein with a high degree of specificity.
  • L-selectin on the leukocytes would be used to bind to a carbohydrate ligand on the filter material.
  • the receptor (lectin) is fixed to the filter, while in the latter the receptor (L-selectin) is intrinsic to the leukocyte.
  • Lectins specific to leukocyte surface structures are derived from various plant and animal sources. However, proteins are not as durable as carbohydrates, and this is a factor in fastening them to the surfaces of polymers and having them stay viable there for a period of time.
  • the preferred approach is to use carbohydrates to bond the L-selectin on the leukocyte surfaces.
  • acrylamide is added to the filter material to prevent platelet adhesion to the whole blood filter.
  • the media As shown in detail in Figure 8, by treating the media with sodium hydroxide, there were activated sizes for polymerization on the GF/L.
  • the media is then covered by polyacrylamide using a special procedure in which the acrylamide monomer solution is flowing through the media under vacuum to prevent poor clogging.
  • This embodiment allows a filter to be used which only has attached thereto an acrylamide, thereby lowering the cost and complexity involved in making a filter media.
  • the present invention can include at least one additional filter to perform normal filtering operations .
  • the present invention also includes a method of removing leukocytes from a fluid, such as blood, by passing the fluid containing the leukocytes through a biologically-active filter for selectively and biochemically binding and retaining the leukocytes to the filter from the fluid.
  • a fluid containing leukocytes can be applied to a biologically-active filter media as discussed- above thereby specifically binding and removing the leukocytes from the fluid while allowing the remainder of the fluid to pass.
  • Plastic sheets AIN Plastics, Inc., Southfield, Michigan were cut to the size of microscope slides to use as models for the plastic material of porous filter webs. Of the many materials available as both fibrous media and as plastic sheets, nylon-6, 6 and polyester have potentially reactive functional groups that can be used for covalent immobilization.
  • Immobilization Methods The surface of the slides was hydrolyzed in warm NaOH solution which produced free amine groups (from nylon, a polyamide) and free hydroxyls (from the polyester) as well as free carboxylic acids (from both) . These functional groups are know to react with a variety of coupling compounds useful for immobilization. Ethylene glycol diglycidyl ether (EGDGE) were used since it is a water soluble di- epoxide known to react with hydroxyls on membranes and filters (Klein et al . , 1994). The surfaces of the slides were reacted with one of the two epoxides of EGDGE.
  • EGDGE Ethylene glycol diglycidyl ether
  • EGDGE epoxide of EGDGE was reacted with the hydroxyls on either of two ligands: Fucoidan or D-mannose-6-phosphate .
  • Three variations of ligand and concentrations were tried, as described below.
  • two variations of immobilizing the saccharides in one step were attempted by combining them with EGDGE.
  • the sixth variation was a control (NaOH hydrolysis, but no EGDGE and no ligand) . These immobilizations were done on only the right hand side of the slide; the left hand side (EGDGE but no ligand) served as a internal control .
  • Test Results 10 ml of PRBC (CPDA-1) were allowed to flow over the treated surface of the slides for 12 minutes. The slides were then washed in buffer, fixed, stained with Wright- Giemsa, and examined visually and microscopically. This demonstrated enhanced binding and aggregation of leukocytes by EGDGE-coated slides (both nylon and polyester) treated with 4% fucoidan, or 8% mannose phosphate, or 4% mannose phosphate plus 50% organic wetting agent, compared to the controls. There was no leukocyte binding to control surfaces lacking carbohydrate ligands. Two treatments of 10% fucoidan plus 1%
  • EGDGE one on EGDGE-coated slides, the other on hydrolyzed slides without EGDGE pretreatment gave mixed results; but not as good as the first three.
  • L-selectin is a labile leukocyte adhesion receptor
  • Figure 2 illustrates the number of leukocytes per microliter separated from whole blood using magnetic beads coated with anti-CD62L versus beads coated with mouse IgG.
  • the number of leukocytes separated by beads coated with anti- CDG2L (anti-L-selectin) antibody was significantly greater than the amount of cells separated by control beads. L-selectin expression was stable over twenty-four hours.
  • Figures 3 and 4 illustrate binding of anti-CD-62L coated beads to the major leukocyte subpopulations proportionate to their numbers in whole blood over twenty-four hours. Due to small numbers of monocytes, and eosinphils, experimental errors are relatively large in these graphs. Basophils, while not plotted, were also adherent to anti-CD62L coated beads but not to control beads. In this experiment cells had less interaction opportunities with the surface of the beads than would be present in a filter device. Thus the number of leukocytes removed by this technique was significantly less than would occur in a filter device based on the same principles, and this may have limited our detection accuracy.
  • L-selectin expression was basically stable under these storage conditions for over twenty-four hours.
  • Neutrophils, lymphocytes, monocytes, eosinophils, and basophils bound anti-CD62L coated beads proportionately to their numbers in whole blood.
  • samples incubated with anti-CD62L beads contained aggregates of leukocytes in which one or more leukocytes that had no attached beads were adherent to a leukocyte with attached beads. No such aggregates, and significantly fewer total aggregates, were seen in control samples. This suggests that leukocytes bound through L-selectin may express other adhesion molecules leading to secondary interactions. This is consistent with the results of Stockl, et al (1993) .
  • Example 2 Example 2
  • the results presented here are based on using galactose 10 mg, amelene stabilized chloroform 2.5 ml, methacrylic acid 0.5 ml, trimethylopropane tri ethacrylate 1.5 ml, and 1, 1' -1, 1-azodi- (hexanhydorbenzonitrile) 50 mg (as the free-radical initiator) .
  • the mixture was deoxigenized for at least ten minutes by a stream of N 2 .
  • the reaction was initiated by irradiation of long wave (366 nm) UVB for 24 hours.
  • the control polymer was synthesized in identical conditions but without galactose.
  • the polymer was dried for about 72 hours and ground to fine particles (a spectrum of sizes) . Then the template molecule was washed away with methanol : acetic acid: water (1:1:1) by five consective washings of 50 ml each. The control polymer underwent the same procedure. The polymer was then washed five times with phosphate buffer solution.
  • Figure 5 illustrates one set of results, including inhabitation by free template molecules (galactose)
  • Figure 6 shows a similar experiment without inhibition.
  • the standard technique for hemoglobin determination Sigma was used to observe decrease in overall hemoglobin in galactose imprinted and control samples, and these results are presented in Figure 7 for the case first.
  • These results demonstrate the efficacy of the imprinting polymer technique in blood cell separation.
  • Example 3 Data how to prevent platelet adhesion on polymer surfaces were published recently. For example, M. Amiji and K. Park studied the fibrinogen adsorption and platelet adhesion onto dimethyldichlorosilane-treated glass and low- density polyethylene.
  • Control Three layers of non- treated GF/L in a 13 mm housing; 2.
  • AS-control Three layers of non- treated GF/L washed with antistatic solution (0.2ml Tween-20 in 11 of saline);

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • External Artificial Organs (AREA)

Abstract

L'invention concerne un ensemble (10) filtre pour enlever des leucocytes d'un liquide. L'ensemble (10) comprend un boîtier (12) définissant une chambre (14), une entrée (16) disposée en communication fluidique avec la chambre (14) permettant au fluide de s'écouler à l'intérieur de la chambre (14), et une sortie (18) disposée en communication fluidique avec ladite chambre (14) permettant au fluide de s'écouler hors de la chambre (14). Un milieu (20) filtrant biologiquement actif est placé à l'intérieur de la chambre (14) pour enlever des leucocytes du fluide s'écoulant à travers l'ensemble (10). Un tel milieu (20) permettant d'enlever des leucocytes d'un fluide comprend à cet effet des fractions biologiquement actives. L'invention traite en outre d'un procédé permettant d'enlever des leucocytes d'un fluide, qui consiste à faire passer un fluide contenant des leucocytes à travers un milieu (20) filtrant biologiquement actif, qui lie et retient sélectivement et biochimiquement lesdites leucocytes.
PCT/US2000/006003 1999-03-11 2000-03-08 Ensemble filtrant de leucocytes, milieu et procede WO2000053287A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35168/00A AU3516800A (en) 1999-03-11 2000-03-08 Leukocyte filter assembly, media, and method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26667199A 1999-03-11 1999-03-11
US09/266,671 1999-03-11

Publications (1)

Publication Number Publication Date
WO2000053287A1 true WO2000053287A1 (fr) 2000-09-14

Family

ID=23015529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006003 WO2000053287A1 (fr) 1999-03-11 2000-03-08 Ensemble filtrant de leucocytes, milieu et procede

Country Status (2)

Country Link
AU (1) AU3516800A (fr)
WO (1) WO2000053287A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892949A1 (fr) * 2005-11-08 2007-05-11 Maco Pharma Sa Unite de filtration des leucocytes a adhesion des plaquettes reduites
US7571744B2 (en) 2001-01-31 2009-08-11 Hemerus Medical, Llc Multi-purpose tubing apparatus
US8114197B2 (en) 2009-12-22 2012-02-14 Hollingsworth & Vose Company Filter media and articles including dendrimers and/or other components
US9782707B2 (en) 2014-03-24 2017-10-10 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US9796166B2 (en) 2014-03-24 2017-10-24 Fenwal, Inc. Flexible biological fluid filters
US9968738B2 (en) 2014-03-24 2018-05-15 Fenwal, Inc. Biological fluid filters with molded frame and methods for making such filters
US10159778B2 (en) 2014-03-24 2018-12-25 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US10376627B2 (en) 2014-03-24 2019-08-13 Fenwal, Inc. Flexible biological fluid filters

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4936998A (en) * 1986-03-28 1990-06-26 Asahi Medical Co., Ltd. Filter medium for selectively removing leucocytes
US5407581A (en) * 1992-03-17 1995-04-18 Asahi Medical Co., Ltd. Filter medium having a limited surface negative charge for treating a blood material
WO1995018665A1 (fr) * 1994-01-10 1995-07-13 Hemasure, Inc. Dispositif et procede pour retirer du sang des leucocytes et des agents viraux inactivants
US5639376A (en) * 1994-01-10 1997-06-17 Hemasure, Inc. Process for simultaneously removing leukocytes and methylene blue from plasma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4936998A (en) * 1986-03-28 1990-06-26 Asahi Medical Co., Ltd. Filter medium for selectively removing leucocytes
US5407581A (en) * 1992-03-17 1995-04-18 Asahi Medical Co., Ltd. Filter medium having a limited surface negative charge for treating a blood material
WO1995018665A1 (fr) * 1994-01-10 1995-07-13 Hemasure, Inc. Dispositif et procede pour retirer du sang des leucocytes et des agents viraux inactivants
US5639376A (en) * 1994-01-10 1997-06-17 Hemasure, Inc. Process for simultaneously removing leukocytes and methylene blue from plasma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMIJI M. ET AL.: "Prevention of protein adsorption and platelet adhesion on surfaces by PEO/PPO/PEO triblock copolymers", BIOMATERIALS, vol. 13, no. 10, 1992, pages 682 - 692, XP002927186 *
FUJIMOTO K. ET AL.: "Polythane surface modification by graft polymerization of acrylamide for reduced protein adsorption and platelet adhesion", BIOMATERIALS, vol. 14, no. 6, 1993, pages 442 - 448, XP002927185 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7571744B2 (en) 2001-01-31 2009-08-11 Hemerus Medical, Llc Multi-purpose tubing apparatus
US8640738B2 (en) 2001-01-31 2014-02-04 Haemonetics Corporation Multi-purpose tubing apparatus
FR2892949A1 (fr) * 2005-11-08 2007-05-11 Maco Pharma Sa Unite de filtration des leucocytes a adhesion des plaquettes reduites
WO2007054638A1 (fr) * 2005-11-08 2007-05-18 Maco Pharma Unite de filtration des leucocytes a adhesion des plaquettes reduite
US8114197B2 (en) 2009-12-22 2012-02-14 Hollingsworth & Vose Company Filter media and articles including dendrimers and/or other components
US8956437B2 (en) 2009-12-22 2015-02-17 Hollingsworth & Vose Company Filter media and articles including dendrimers and/or other components
US9782707B2 (en) 2014-03-24 2017-10-10 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US9796166B2 (en) 2014-03-24 2017-10-24 Fenwal, Inc. Flexible biological fluid filters
US9968738B2 (en) 2014-03-24 2018-05-15 Fenwal, Inc. Biological fluid filters with molded frame and methods for making such filters
US10159778B2 (en) 2014-03-24 2018-12-25 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US10183475B2 (en) 2014-03-24 2019-01-22 Fenwal, Inc. Flexible biological fluid filters
US10343093B2 (en) 2014-03-24 2019-07-09 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US10376627B2 (en) 2014-03-24 2019-08-13 Fenwal, Inc. Flexible biological fluid filters

Also Published As

Publication number Publication date
AU3516800A (en) 2000-09-28

Similar Documents

Publication Publication Date Title
US5085781A (en) Separating agent, separator and method of separating cell or virus
EP0987325B1 (fr) Procede de separation des cellules
CA2490245C (fr) Dispositifs de filtration tangentielle et methodes d'enrichissement des leucocytes
US6544751B1 (en) Methods of harvesting rare cells from blood products
DE69332926T2 (de) Kontinuierliches zentrifugationsverfahren zum abtrennen von biologischen komponenten aus heterogenen zellpopulationen
Faradji et al. Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients
JP6722023B2 (ja) 細胞分離フィルター、及びこれを利用した細胞濃縮液の製造方法
EP0792677A1 (fr) Dispositif et milieux de filtration pour enlever des leucocytes et méthode d'emploi
WO2000053287A1 (fr) Ensemble filtrant de leucocytes, milieu et procede
WO2002101029A1 (fr) Methode de separation et de concentration cellulaires pour la regeneration renale
US20020031757A1 (en) Method of regenerating a tissue
EP1484390A1 (fr) Méthode de préparation de cellules-souches périphériques à partir de filtres de réduction des leucocytes
JPH03270701A (ja) 遠心分離管および細胞の分離方法
JP3939391B2 (ja) 細胞除去方法
KR100229579B1 (ko) 개질 키토산으로 도포된 백혈구 제거용 필터
JP4583325B2 (ja) 吸着材の処理方法
CA2553407A1 (fr) Cellules mononuclees de sang peripherique
JPH11266852A (ja) 細胞分離器
US20040224300A1 (en) Method for separating nucleated cells
JPS60126165A (ja) 血液適合性吸着材
Marcus et al. CFU‐GM and T cell subsets in young red cell collections
Nordon et al. Cell separation
JPH07120452A (ja) 細胞の選択的分離方法
JPH04346801A (ja) リンパ球サブクラス分離剤、分離装置および分離方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase